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1. INTRODUCTION 2. UNCOUPLING 
Cholesterol, an essential component of all living 
cells and of many cellular structures, is either ob- 
tained from the diet or from de novo synthesis. 
Hydroxymethylglutaryl-CoA reductase (HMG- 
CoA reductase), the principal rate-limiting enzyme 
for de novo synthesis of cholesterol, plays a key 
role in the regulation of cholesterogenesis. 
The symposium described below was devoted to 
many aspects of the regulation of HMG-CoA 
reductase. The topics ranged from basic 
biochemistry and molecular biology through plant 
biology and medicine. The multidisciplinary 
character of this meeting (Reductase IV) con- 
formed with previous symposia organized around 
the same subject: Atlantic City, USA (1973), 
Toronto, Canada (1979) and San Francisco, USA 
(1983). Organized as a satellite conference of the 
13th IUB Meeting in Amsterdam and supported by 
donations from industry, Reductase IV comprised 
12 short lectures, 23 posters and a panel discussion 
that dealt with an overview of the field. The 
following topics were discussed. 
In regenerating rat liver, the classic correlation 
between the rate of cholesterol biosynthesis and 
the activity of HMG-CoA reductase is lost 
(Bruscalupi, Leoni, Mangiantini, Marino, Minieri, 
Spagnuolo, Valbonesi, Hemming and Trentalance, 
Rome). Such uncoupling of the activity of HMG- 
CoA reductase from the rate of cholesterogenesis 
is not unique. The uncoupling suggests that the in- 
tracellular HMG-CoA concentration may fall well 
below saturation level for HMG-CoA reductase, 
thereby limiting the rate of cholesterol synthesis. It 
was proposed that compensatory adjustment of 
reductase activity serves to maintain homeostasis 
of cholesterol synthesis in response to changing 
substrate availability (Gibbons and Pullinger, 
Oxford). 
3. NON-MAMMALIAN HMG-CoA 
REDUCTASES 
* Symposium abstracts will be published in full in the 
Journal of Lipid Research (May, 1986) 
Several contributions reported the purification 
and properties of HGM-CoA reductase from non- 
animal sources. In radish seedlings, light decreased 
reductase levels. Enzyme preparations recovered 
from dark-grown seedlings yielded a hydrophobic 
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protein with an apparent molecular mass of 
180 kDa with subunits of 45 kDa and apparent K,,, 
values of 1.5 and 27 PM for HMG-CoA and 
NADPH, respectively (Bach, Karlsruhe). In 
Pseudomonas M, HMG-CoA reductase functions 
as part of a catabolic pathway and is induced when 
the organism is grown on mevalonate. 
Pseudomonas M reductase appears to be a 
tetramer with identical subunits of 43 kDa. The 
amino acid sequence of reductase from 
Pseudomonas M does not indicate any homology 
with that of reductase from CHO cells (Beach, 
Hermodson and Rodwell, West Lafayette). 
In Saccharomyces cerevisiae, HMG-CoA reduc- 
tase is localized in both mitochondria and en- 
doplasmic reticulum. The activity in both compart- 
ments increases under catabolite-repressed, as well 
as catabolite-derepressed, conditions. Whether the 
two activities are isoenzymes or modified forms of 
the same enzyme is uncertain (Haslam, Birch and 
Crabbe, Liverpool). 
4, MEMBRANE COMPOSITION 
Studies with cholesterol feeding in chicks con- 
firmed and extended prior observations indicating 
a close relationship between the lipid composition 
of liver microsomal membranes and the activity of 
HMG-CoA reductase (Alejandre, Garcia, Gon- 
zales, Garcia and Segovia, Granada). A different 
approach to the relationship of microsomal lipid 
composition and HMG-CoA reductase activity 
employed isolated microsomes incubated with lipid 
vesicles in the absence or presence of a lipid ex- 
change protein. Enrichment of microsomes with 
cholesterol or saturated phospholipids decreased 
membrane fluidity and reduced the activity of 
HMG-CoA reductase (Davis and Poznansky, Ed- 
monton). Another promising strategy for studying 
lipid-reductase interactions is represented by in- 
vestigation of the properties of HMG-CoA reduc- 
tase which has been solubilized and then integrated 
in synthetic liposomes of known composition 
(Ramirez, Rodriguez, Marco and Garcia-Peregrin, 
Granada). The lipid environment of HMG-CoA 
reductase was also changed by incorporation of 
polychlorinated biphenyls into the microsomal 
membrane. These industrial contaminants in our 
environment presumably by altering the 
enzyme-lipid interaction directly affected reduc- 
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The activity of HMG-CoA reductase can be 
modulated by phosphorylation-dephosphoryla- 
tion. Two new in vitro phosphorylating systems 
were introduced: (i) reductase can be phosphory- 
lated (on serine residues) and inactivated by pro- 
tein kinase C, and (ii) also by a distinct Ca’+, 
calmodulin-dependent protein kinase (Beg, Stonik 
and Brewer, Bethesda). Inactivation of HMG-CoA 
reductase coincident with phosphorylation of its 
serine residues was also observed following treat- 
ment with homogeneous reductase kinase purified 
from rat liver cytosol in the presence of ADP 
(Caelles, Ferrer, Massot, Calvet and Hegardt, 
Barcelona). Activation of HMG-CoA reductase 
can be achieved with several, kinetically distinct 
phosphoprotein phosphatases derived from rat 
liver microsomes. These phosphatases differ in 
their ability to activate the reductase and to inac- 
tivate cholesterol 7cu-hydroxylase and acyl-CoA 
cholesterol acyltransferase (ACAT), enzymes also 
reported to be regulated by phosphoryla- 
tion-dephosphorylation (Diven, Sweeney and 
Sanghvi, Pittsburgh). Short-term regulation of in- 
testinal HMG-CoA reductase activity by phospho- 
rylation-dephosphorylation resembles in many 
ways the regulation of the liver enzyme. In contrast 
to the previously characterized ADP-dependent 
liver reductase kinase, dinucleotides failed to af- 
fect the intestinal kinase (Sugano, Oku and Ide, 
Fukuoka). 
6. DEGRADATION-SYNTHESIS 
The concept that covalent phosphorylation of 
HMG-CoA reductase increases the rate of its 
degradation was highlighted by two contributions. 
Incubation of hepatocytes with mevalonate for 
5 min enhanced incorporation of 32P into reduc- 
tase 70% over controls. This initial response was 
followed by an increase in the rate of degradation 
of the enzyme (Haro, Marrero, Asins, Serra, Royo 
and Hegardt, Barcelona). Related evidence, ob- 
tained using immunoblots, also demonstrated that 
the degradation rate of HMG-CoA reductase in 
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isolated hepatocytes was increased by products of 
mevalonate metabolism and by oxysterols. In vitro 
evidence was presented indicating that covalent 
phosphorylation of microsomal HMG-CoA reduc- 
tase increased its susceptibility to proteolytic 
degradation by calcium-dependent neutral pro- 
tease (Parker, Miller and Gibson, Indianapolis). In 
studies with hamster adrenal microsomes the 
specific activity of HMG-CoA reductase was in- 
creased by limited proteolysis (Preiss and Delisle, 
Quebec). 
Two contributions were devoted to regulation of 
adrenal gland HMG-CoA reductase synthesis. 
Adrenocorticotropin (ACTH) stimulation of 
hamster adrenals increased HMG-CoA reductase 
activity. This response was blocked with cyclohex- 
imide, indicating that de novo protein synthesis is 
involved in the response. An increase in reductase 
mRNA in the adrenals after ACTH stimulation is 
consistent with that notion (Leloux, Bellabarba, 
Belisle and Lefebvre, Sherbrooke). ACTH in- 
creased reductase activity 5-lo-fold above basal 
levels in sheep adrenocortical cells. Use of anti- 
bodies against rat liver reductase suggested that the 
increased activity in response to ACTH probably is 
the result of increased enzyme synthesis, not of en- 
zyme activation (Mason, Magness and Rainey, 
Dallas). 
7. OXYSTEROLWBINDING PROTEINS 
Several contributions supported the emerging 
concept that ongoing endogenous terol synthesis 
is required for LDL-cholesterol to down-regulate 
HMG-CoA reductase, and that LDL-derived 
cholesterol does not itself affect reductase activity. 
In Hep G2 cells, low concentrations of U1866A (an 
inhibitor of oxidosqualene cyclase) inhibited sterol 
synthesis as well as the activity of HMG-CoA 
reductase. This agent favoured accumulation of a 
polar sterol which may be the immediate effect in 
lowering reductase activity (Cohen, Bogaard and 
Kempen, Leiden). Related evidence was obtained 
in studies with a fibroblast mutant deficient in 
squalene synthase. This mutant exhibits normal 
suppression of HMG-CoA reductase activity by 
25-OH cholesterol and mevalonate, but not by 
LDL-cholesterol. The mevalonate ffect on reduc- 
tase activity implies that a pre-squalene derivative 
of mevalonate may function in reductase regula- 
tion (Sinensky and Logel, Denver). Experiments 
with a mutant CHO cell line defective in HMG- 
CoA synthase indicate that control of HMG-CoA 
reductase synthesis by 25OH cholesterol, and 
notably by products of mevalonate metabolism oc- 
curs at the translational evel (Peffley and Sinen- 
sky, Denver). Complementary evidence that LDL- 
derived cholesterol does not directly regulate 
reductase activity was obtained using skin 
fibroblast and intestinal epithelial cells. In these 
studies, progesterone and inhibitors of cytochrome 
P450, cytochrome P450-dependent lanosterol 14~ 
demethylase and oxidosqualene cyclase, prevented 
LDL-suppression of HMG-CoA reductase. The 
results further suggest that down-regulation of 
HMG-CoA reductase by LDL is mediated via a 
cytochrome P450-dependent formation of ox- 
ysterols generated from either endogenous precur- 
sors or from LDL-cholesterol (Gupta, Shertzer 
and Rudney, Cincinnati; Gupta, Sexton and 
Rudney, Cincinnati). A defect in the down- 
regulation of HMG-CoA reductase by LDL- 
cholesterol may be present in Alagille syndrome, in 
which extremely high levels of serum cholesterol 
fail to suppress reductase activity in skin 
fibroblasts (DuPont, Raulin, Lapous, Loriette and 
Gautier, Ames/Paris). 
Oxysterols may be transported from their site of 
formation to the ultimate site of action by a 
specific oxysterol binding protein. The existence of 
such a protein has been demonstrated in rat liver. 
This protein preferentially binds cholesterol 
derivatives oxidized on the side chain. Cholesterol, 
squalene and oxidosqualene are not bound 
(Beseme, Astruc, Defay and Crastes de Paulet, 
Montpellier). Several other sterol carrier proteins 
have also been identified in rat liver. In search for 
an in vivo function of one of these proteins (sterol 
carrier protein-2) studies were performed with in- 
bred strains of rats in which the rate of bile acid 
synthesis varies. The results suggest hat sterol car- 
rier protein-2 may be associated with bile acid 
metabolism rather than with cholesterol synthesis 
or esterification (Geelen, Beynen and Vaartjes, 
Utrecht). 
8. MOLECULAR BIOLOGY 
A study of hormonal regulation of expression of 
HMG-CoA reductase revealed that thyroid hor- 
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manes regulate expression of the reductase gene at 
the level of transcription while glucocorticoids and 
insulin exert their effects at post-translational 
levels (Ness, Sample and Pendleton, Tampa). A 
related study on regulation of cholesterol biosyn- 
thesis and expression of HMG-CoA reductase at 
the molecular level was concerned with the HMG- 
CoA reductase gene and its cDNA. For that pur- 
pose rat liver reductase cDNA clones have been 
isolated, identified and characterized (Khan, 
Kabat and Stambrook, Cincinnati; Shapiro, 
Gould, Martin, Williams and Wolski, Urbana). 
The latter study also showed that rat liver reduc- 
tase mRNA consists at least of two species which 
differ in size by approx. 500 nucleotides. The 
possibility that the two mRNAs code for distinct 
polypeptides separately targeted for ER and for 
peroxisomes, recently shown to contain HMG- 
CoA reductase, has been raised (Shapiro, Gould, 
Martin, Williams and Wolski, Urbana). 
9. CLINICAL STUDIES 
Several contributions concerned problems of 
clinical relevance. Studies with microsomes of 
freshly isolated monocytes from healthy subjects 
and from patients with familial hyper- 
cholesterolemia (FH) suggested that the monocyte 
LDL receptor has no function in the down- 
regulation of HMG-CoA reductase activity. In ad- 
dition, this study indicated that stimulation of en- 
dogenous cholesterol synthesis may contribute to 
the rapid restoration of circulating cholesterol 
levels in patients with FH who undergo periodic 
therapeutic plasma exchange (Stacpoole, Bridge 
and Harwood, Gainesville). Hormonal effects on 
the activity of microsomal HMG-CoA reductase 
have been investigated in hepatocytes maintained 
in monolayer culture for 3 h. Insulin and 
catecholamines increased HMG-CoA reductase ac- 
tivity 4- and 2.5fold, respectively. In the presence 
of catecholamines, insulin-enhancement of enzyme 
activity was reduced to the catecholamine-induced 
activity level. This observation may explain the low 
HMG-CoA reductase activity seen in poorly con- 
trolled diabetic animals in which catecholamine 
levels are high (Devery and Tomkin, Dublin). 
HMG-CoA reductase in microsomes from cultured 
or freshly isolated human leucocytes is markedly 
inhibited by physiological concentrations of ascor- 
bic acid in the leucocytes. This inhibition is not due 
to ascorbic acid-induced modification of mem- 
brane lipids since ascorbic acid also inhibited the 
partially purified human liver enzyme. Thus, this 
vitamin may be of importance in the regulation of 
endogenous cholesterol synthesis in man (Har- 
wood, Greene and Stacpoole, Gainesville). Syn- 
thetic inhibitors of HMG-CoA reductase, related 
to HMG and coenzyme A were reported (Deana, 
Lippe, Cavallini, Quadro and Galzigna, Milan). 
10. CELL CYCLE AND DEVELOPMENT 
The suggestion, obtained from studies with syn- 
chronized cells, that the activity of HMG-CoA 
reductase and the rate of sterol synthesis are 
dependent on the phase of the cell cycle was not 
substantiated in a study using continuously pro- 
liferating LM cells in culture. In these non-trans- 
formed cells the activity of the de novo sterol syn- 
thetic pathway remained constant throughout the 
cell cycle (Maltese and Sheridan, New York). 
During development microsomal HMG-CoA 
reductase activity in rat liver showed a disconti- 
nuous pattern, i.e. increasing during fetal develop- 
ment, declining towards birth, and rising again 
after weaning. The activation state of reductase 
also varied during development (Leoni, Mangian- 
tini, Spagnuolo, Conti de Virgiliis, Valbonesi and 
Trentalance, Rome). 
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